Biocon Biologics Limited has received positive recognition from S&P Global Ratings, which placed the company on positive credit watch following its accelerated debt reduction initiatives. The rating agency's decision reflects the significant progress being made in strengthening the company's financial position through strategic restructuring.

S&P Rating Action Details

On December 10, 2025, S&P Global Ratings placed its BB long-term issuer credit rating on Biocon Biologics and the BB issuer rating on the senior secured notes issued by the company on credit watch with positive implications. The rating action underscores S&P's view that these developments represent a positive step toward retiring debt and improving the overall capital structure.

Strategic Transaction Structure

The positive credit watch follows Biocon's announcement to make Biocon Biologics a wholly owned subsidiary. The company will acquire approximately 25% stake held by minority investors in Biocon Biologics through equity share swaps. The transaction includes several key components that will significantly reshape the company's capital structure.

Biocon Limited plans to swap compulsory convertible preference shares (CCPS) held by Viatris Inc. in Biocon Biologics by exchanging them for equity shares and cash. The US$1 billion CCPS will be swapped for US$415 million worth of Biocon equity shares and US$400 million in cash. Additionally, Biocon will enable other minority investors to exit Biocon Biologics through similar arrangements.

Debt Reduction Impact

S&P Global's rationale highlights the material decline expected in Biocon's debt levels by March 2026. The rating agency treats the US$1 billion CCPS as debt-like in its financial ratios, making this transaction particularly significant for the company's credit profile.

Importantly, Biocon proposes to fund the cash consideration to be paid to Viatris entirely through fresh equity issuance of approximately ₹45 billion. The transaction eliminates other instruments that carried put options and allowed credit investors an earlier exit, which were previously viewed as debt-like by the rating agency.

Capital Structure Transformation

Proforma the transaction, S&P expects Biocon's capital structure to comprise only senior secured notes, bilateral loans, and working capital borrowings. By March 31, 2026, Biocon will have already repaid other optionally convertible debentures and redeemable non-convertible debentures issued to various investors, primarily through proceeds from its ₹45 billion equity issuance completed earlier in the year.

Credit Watch Resolution Timeline

S&P expects to resolve the credit watch on Biocon Biologics over the next 60-90 days once there is more clarity on the final capital structure and financial policy of the Biocon group. The resolution will depend on the completion of the equity issuance by Biocon to fund the cash payout to Viatris and the elimination of other debt-like instruments under the proposed transaction terms. The transaction remains pending shareholder approvals, and Biocon's ability to raise ₹45 billion through equity issuance is yet to be demonstrated.

Biocon , a leading biopharmaceutical company, has announced plans to explore fundraising options and make strategic investments. The company intends to consider raising funds through commercial paper or share issuance, while also planning to invest in its subsidiary, Biocon Biologics.

Fundraising Exploration

Biocon will evaluate various fundraising avenues, including:

1. Commercial Paper: This short-term debt instrument could provide the company with quick access to capital.
2. Share Issuance: The company may consider issuing new shares to raise equity capital.

Investment in Biocon Biologics

Alongside its fundraising efforts, Biocon plans to invest in Biocon Biologics by purchasing securities from existing shareholders. This move suggests a strategic intent to increase its stake in the subsidiary.

Financial Context

To provide context for these decisions, let's look at Biocon's recent financial position based on its consolidated balance sheet data:

The company's financial position shows growth across key metrics, with total assets increasing by 4.86% and total equity rising by 9.64% compared to the previous year. The increase in investments by 12.73% aligns with the company's plans to further invest in Biocon Biologics.

Implications

Biocon's decision to explore fundraising options while simultaneously planning investments in its subsidiary indicates a strategic approach to capital management and growth. The company appears to be positioning itself for expansion or strengthening its market position in the biopharmaceutical sector.

Investors and market observers will be keenly watching the outcomes of Biocon's deliberations, as they could have significant implications for the company's financial structure and future growth trajectory.